Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03986931 · ClinicalTrials.gov registry record · NA

A Pharmacist Intervention for Monitoring and Treating Hypertension Using Bidirectional Texting

A NA study, sponsored by Linnea Polgreen.

Completed
Registry status
NA
Development phase
535
Enrollment target

NCT03986931 is a NA study that has completed, run by Linnea Polgreen. The registered enrollment target is 535 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03986931, a NA study, has completed, sponsored by Linnea Polgreen.

COMPLETED
Registry status
NA
Development phase
535 participants
Enrollment target

Study Summary

Bidirectional texting is an effective way to collect home blood pressure (BP) measurements from subjects, but collecting BP measurements and sending them to physicians does not necessarily lead to decreased BP. Pharmacist interventions have been successful in decreasing subject BP. However, pharmacists are expensive, and in successful interventions, spent a substantial amount of time collecting home BP measurements. In this study, a proven pharmacist intervention will be added to a bidirectional texting program to determine if a combined pharmacist-bidirectional texting intervention is successful at decreasing subject BP and increasing subject BP treatment intensification in a cost-effective manner. This study will be a cluster-randomized, controlled trial of a new intervention.

Interventions

  • OTHER Experimental: Pharmacist-Bidirectional Texting Group
  • OTHER Active Comparator: Control Group

Trial Details

FieldValue
Enrollment Target 535 participants
Start Date 2020-02-25
Est. Completion 2023-06-22
Phase NA

Sponsor

Linnea Polgreen

4 total trials

What the Registry Record Tells You About NCT03986931

The ClinicalTrials.gov registry entry for NCT03986931 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 535 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Linnea Polgreen, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Experimental: Pharmacist-Bidirectional Texting Group is the first listed.

NCT03986931 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03986931 about?

NCT03986931 is a clinical study titled "A Pharmacist Intervention for Monitoring and Treating Hypertension Using Bidirectional Texting". Bidirectional texting is an effective way to collect home blood pressure (BP) measurements from subjects, but collecting BP measurements and sending them to physicians does not necessarily lead to decreased BP. Pharmacist interventions have been successful in decreasing subject BP. However, pharmaci...

What is the current status of trial NCT03986931?

This trial is currently completed. It is a NA study. The enrollment target is 535 participants. The study started on 2020-02-25. Estimated completion is 2023-06-22.

What interventions are being tested in trial NCT03986931?

The interventions under investigation include: Experimental: Pharmacist-Bidirectional Texting Group (OTHER), Active Comparator: Control Group (OTHER).

Who is sponsoring clinical trial NCT03986931?

This trial is sponsored by Linnea Polgreen, which has 4 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.